GlyCare™ 3FL
One of the most abundant fucosylated HMO
GlyCare™ 3-fucosyllactose overview
3FL (3-Fucosyllactose) is a highly abundant, α1-3 fucosylated HMO in human milk. GlyCare™ 3FL is presently undergoing development.
Immunity and infections
Clinical studies suggest a relationship between HMOs and some immune outcomes in infants. Emerging science suggest that specific HMOs, such as 3 Fucosyllactose, at the correct level of supplementation may help to reduce the risk of certain infections in infants consuming infant formula and in infants who are breastfed. Gut Health and Microbiota
Clinical and preclinical studies report that 3-Fucosyllactose and other HMOs may help to stimulate the growth of beneficial bacteria, which are believed to be important for development of the microbiota and gut health.
Gut health and microbiota
Clinical and preclinical studies report that HMOs may help to stimulate the growth of beneficial bacteria, which are believed to be important for development of the microbiota and gut health. Evidence from preclinical studies suggests 3’FL may have a role in gut health via its positive impact on the growth of bifidobacteria which are considered to be beneficial for gut health3,4,5.
References
1. Weichert, S., Jennewein, S., Hüfner, E., Weiss, C., Borkowski, J., Putze, J., & Schroten, H. (2013). Bioengineered 2’-fucosyllactose and 3-fucosyllactose inhibit the adhesion of Pseudomonas aeruginosa and enteric pathogens to human intestinal and respiratory cell lines. Nutrition Research, 33(10), 831–838. https://doi.org/10.1016/j.nutres.2013.07.009
2. Brassart, D., Woltz, A., Golliard, M., & Neeser, J. R. (1991). In vitro inhibition of adhesion of Candida albicans clinical isolates to human buccal epithelial cells by Fucα1→2Galβ-bearing complex carbohydrates. Infection and Immunity, 59(5), 1605–1613. https://doi.org/10.1128/iai.59.5.1605-1613.1991
3. Yu, Z. T., Chen, C., Kling, D. E., Liu, B., McCoy, J. M., Merighi, M., … Newburg, D. S. (2013). The principal fucosylated oligosaccharides of human milk exhibit prebiotic properties on cultured infant microbiota. Glycobiology, 23(2), 169–177. https://doi.org/10.1093/glycob/cws138
4. Ashida, H., Miyake, A., Kiyohara, M., Wada, J., Yoshida, E., Kumagai, H., … Yamamoto, K. (2009). Two distinct α-L-fucosidases from Bifidobacterium bifidum are essential for the utilization of fucosylated milk oligosaccharides and glycoconjugates. Glycobiology, 19(9), 1010–1017. https://doi.org/10.1093/glycob/cwp082
5. Schwab, C., & Gänzle, M. (2011). Lactic acid bacteria fermentation of human milk oligosaccharide components, human milk oligosaccharides and galactooligosaccharides. FEMS Microbiology Letters, 315(2), 141–148. https://doi.org/10.1111/j.1574-6968.2010.02185.x
HMO health benefits & solutions
Human milk oligosaccharides may support a number of health benefits such as immunity and gut health in early life.
Related articles
-
It takes guts and science: Unlock the latest research behind human milk oligosaccharides (HMOs) for human health
-
Supporting the infant microbiome: Exploring the science of synergistic synbiotics at ESPGHAN 2024
-
Explore the science behind synbiotic solutions combining HMOs and probiotics plus their benefits for infant health and development.
How can we help you?
-
New product concept
Got a notion for your next project or breakthrough innovation? Let’s put our heads together.
-
Sample request
Don’t just take our word for it. Discover how our solutions can support your product development journey.
-
-
Quick links
Customized blends of functional ingredients in one single, efficient premix.
Streamline your product development process and get to market faster.
Solutions to address consumers' health and lifestyle needs, giving you an edge in the market.
Talking Nutrition, Health & Care
Explore new science, consumer insights, industry news and more in our latest articles.
Discover educational whitepapers, webinars, publications and technical information.
Request samples, place orders and view product documentation.